Abstracts tagged "Disease Activity"

Abstract Number: 0657 • ACR Convergence 2024
Data-driven Bayesian Network Analysis for Predicting Difficult-to-treat (DTT) Lupus Nephritis
Jagan K L¹, Augustine Jose², Vishnupriya G¹, Dellan S¹, Dhanush S¹, Samskruthi Reddy Tokala¹, Bhavana Mashetty¹, Chengappa Kavadichanda³, Sachith ganapathy¹, Aishwarya Gopal⁴, Rithik Roshan¹, Sareddy Sai vignesh Reddy¹, Sonal Mehra⁵, Molly Thabah¹ and Vir Singh Negi⁶, ¹Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, Puducherry, India, ²Jawaharlal Institute of Postgraduate Medical Education and Research, Gorimedu, Puducherry, India, ³Jawaharlal Institute of Postgraduate Medical Education and Research, pondicherry, Puducherry, India, ⁴Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Pondicherry, Puducherry, India, ⁵JAYPEE HOSPITAL, Noida, Uttar Pradesh, India, ⁶AIIMS, Bilaspur, Puducherry, Puducherry, India
Background/Purpose: Lupus nephritis (LN) is a serious manifestation of systemic lupus erythematosus (SLE), with 14-33% failing to respond to standard treatments. This study assesses treatment…
Abstract Number: 1025 • ACR Convergence 2024
Gender Disparities in Disease Impact and Treatment Access for Spondyloarthropathies in Latin America: Insights from a Web Survey
Sebastián Ibáñez¹, María Dominga García¹ and Natalia González², ¹Clínica Alemana de Santiago, Santiago, Region Metropolitana, Chile, ²Fundación Espondilitis Chile, Santiago, Region Metropolitana, Chile
Background/Purpose: Previous studies have shown that female patients with spondyloarthritis (SpA) tend to experience a greater impact on their functionality, especially among women in Latin…
Abstract Number: 1337 • ACR Convergence 2024
Gender and Ethnic Differences (or Lack Thereof) in Perceived Disease Burden in RA
Ali Malik¹, Dennis Ang¹, Adam Hall¹, John Herion¹ and Rupak Thapa², ¹Wake Forest University, Winston Salem, NC, ²Assistant Professor, Winston Salem, NC
Background/Purpose: Gender and ethnic disparities in health care are well reported in the general medical literature. Differences in symptom reporting or perceived health status can…
Abstract Number: 1397 • ACR Convergence 2024
Temporal Trends in Early Rheumatoid Arthritis (ERA) Patients with Moderate to Severe Disease Activity: A Multicenter Cohort Study of Treatment Strategies and Outcomes in Chinese Patients in the Modern Era
Yafang Deng¹, Chen Yu², Lin Qiao¹, Nan Jiang¹, Yanhong Wang³, Xinping Tian¹, Qian Wang¹, Mengtao Li⁴ and Xiaofeng Zeng¹, ¹Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, ²Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Dong Cheng Qu, China (People's Republic), ³Department of Epidemiology and Biostatistics, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, ⁴Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China 2National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science & Technology, Beijing, China
Background/Purpose: In the contemporary era, the continuous update of international rheumatoid arthritis (RA) guidelines has significantly impacted the diagnosis and management of RA patients in…
Abstract Number: 1681 • ACR Convergence 2024
Safe Switching from Originator Tocilizumab to MSB11456 Tocilizumab Biosimilar in Subjects with Moderate-to-Severe Rheumatoid Arthritis: Efficacy, Safety and Immunogenicity Data Following Treatment Transition in a Pivotal, Randomized, Double-blind, Phase III Study
Anna Zubrzycka-Sienkiewicz¹, Kamilla Klama², Martin Ullmann³, Corinne Petit-Frere³, Andras Illes³, Olga Menang³, Joëlle Monnet³ and Peter Baker³, ¹Reumatika - Centrum Reumatologil", NZOZ, Warszawa, Poland, ²Solumed Centrum Medyczne, Poznań, Poland, ³Fresenius Kabi SwissBioSim GmbH, Eysins, Switzerland
Background/Purpose: A therapy transition from the originator to a biosimilar offers significant advantages for patients by lowering medication costs and improving accessibility to treatments. MSB11456…
Abstract Number: 2026 • ACR Convergence 2024
Cardiovascular Risk Measured by PREVENT Calculator and Disease Activity in Patients with Systemic Lupus Erythematosus
Rebeca L. Polina-Lugo¹, Aleydis Gonzalez Melendez¹, Maria F. Elizondo-Benitez², Andrea Guajardo Aldaco¹, Annette Dominguez-Guerra³, Victoria P. Limas-Martínez¹, Iris Jazmín Colunga Pedraza¹, Dionicio Galarza-Delgado⁴, jose Ramon Azpiri-Lopez⁵, Rosa Icela Arvizu-Rivera¹ and Jesus Cardenas-de la Garza⁶, ¹Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, ²Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo León, Mexico, ³Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo León, Mexico, ⁴UANL Hospital Universitario, Monterrey, Nuevo León, Mexico, ⁵Division of Cardiology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, ⁶Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico
Background/Purpose: Increased disease activity by SLEDAI (Systemic Erythematosus Lupus Disease Activity Index) has been associated with higher cardiovascular risk (CVR) and atherosclerotic cardiovascular disease (ASCVD),…
Abstract Number: 2325 • ACR Convergence 2024
Predictors of Treatment Response and Continuation in Patients with Psoriatic Arthritis Initiating Secukinumab – Results from the EuroSpA Collaboration
Stylianos Georgiadis¹, Mikkel Ostergaard², Jette Heberg³, Zohra Faizy Ahmadzay⁴, Brigitte Michelsen⁵, Simon Horskjær Rasmussen⁶, Mehrdad Kazemi⁶, Johan Karlsson Wallman⁷, Tor Olofsson⁸, Bente Glintborg⁹, Anne Gitte Loft¹⁰, Isabel Castrejón¹¹, Ladislav Šenolt¹², Michael J. Nissen¹³, Burkhard Moeller¹⁴, Jorge Garcia¹⁵, Filipe Barcelos¹⁶, Ziga Rotar¹⁷, Katja Perdan-Pikmajer¹⁷, Catalin Codreanu¹⁸, Corina Mogosan¹⁸, Karin Laas¹⁹, Sigrid Vorobjov²⁰, Bjorn Gudbjornsson²¹, Gerdur Gröndal²¹, Dan Nordstrom²², Anna-Mari Hokkanen²³, Pawel Mielnik²⁴, Tore K. Kvien²⁵, Gökçe Kenar²⁶, Marleen Van De Sande²⁷, Merete Hetland²⁸ and Lykke Oernbjerg¹, ¹Rigshospitalet Glostrup, Glostrup, Hovedstaden, Denmark, ²Department of Clinical Medicine, University of Copenhagen and Center for Rheumatology, Copenhagen Center for Arthritis Research, Glostrup, Denmark, ³Rigshospitalet Glostrup, København V, Denmark, ⁴Rigshospitalet Glostrup and Copenhagen University, Glostrup, Denmark, ⁵Rigshospitalet Glostrup, Diakonhjemmet Hospital and Sørlandet Hospital, Copenhagen, Denmark, ⁶Rigshospitalet Glostrup, Glostrup, Denmark, ⁷Lund University, Department of Clinical Sciences Lund, Section of Rheumatology and Skåne University Hospital, Lund, Sweden, Lund, Skane Lan, Sweden, ⁸Lund University, Department of Clinical Sciences Lund, Section of Rheumatology and Skåne University Hospital, Lund, Sweden, Lund, Sweden, ⁹DANBIO, Rigshospitalet Glostrup and University of Copenhagen, Virum, Denmark, ¹⁰Aarhus University Hospital and Aarhus University, Horsens, Denmark, ¹¹Hospital General Universitario Gregorio Marañón and Complutense University of Madrid, Madrid, Spain, ¹²Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ¹³Geneva University Hospital, Geneva, Switzerland, ¹⁴Inselspital - University Hospital Bern, Bern, Switzerland, ¹⁵Clínica Médico Ourém, Ourém, Portugal, ¹⁶Universidade Nova de Lisboa, Instituto Português de Reumatologia and Hospital CUF Descobertas, Lisbon, Portugal, ¹⁷University Medical Centre Ljubljana and University of Ljubljana, Ljubljana, Slovenia, ¹⁸University of Medicine and Pharmacy, Bucharest, Romania, ¹⁹East-Tallinn Central Hospital, Tallinn, Estonia, ²⁰National Institute for Health Development, Tallinn, Estonia, ²¹Landspitali University Hospital and University of Iceland, Reykjavik, Iceland, ²²Helsinki University Hospital, Helsinki, Finland, ²³Helsinki University and Helsinki University Hospital, Helsinki, Finland, ²⁴Helse Førde, Førde, Norway, ²⁵Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway and University of Oslo (UiO), Institute of Clinical Medicine, Oslo, Norway, Oslo, Norway, ²⁶Dokuz Eylul University School of Medicine, Izmir, Turkey, ²⁷Amsterdam Institute for Infection & Immunity and Reade and Amsterdam UMC, Amsterdam, Netherlands, ²⁸Rigshospitalet Glostrup and University of Copenhagen, Glostrup, Denmark
Background/Purpose: Several predictors of treatment response to tumour necrosis factor inhibitors (TNFi) in routine care have been reported in psoriatic arthritis (PsA). However, data on…
Abstract Number: 2481 • ACR Convergence 2024
General, Nervous System, Eye, and Skin Involvement in the Phase 3 Trial of Avacopan for the Treatment of ANCA-Associated Vasculitis
Rula A. Hajj-Ali¹, Duvuru Geetha², Raashid Luqmani³, Christian Pagnoux⁴, Darcy Trimpe⁵, David Jayne⁶ and Peter Merkel⁷, and ADVOCATE Study Group, ¹Cleveland Clinic, Cleveland, OH, ²Johns Hopkins University, Baltimore, MD, ³University of Oxford, Abingdon, United Kingdom, ⁴Mount Sinai Hospital, Toronto, ON, Canada, ⁵Amgen Inc., Thousand Oaks, CA, ⁶University of Cambridge, Cambridge, United Kingdom, ⁷University of Pennsylvania, Philadelphia, PA
Background/Purpose: The most common types of ANCA-associated vasculitis, granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA), can affect a range of organs, including the kidneys,…
Abstract Number: 0412 • ACR Convergence 2024
Impact of Approval of Biologic DMARDs on JIA Outcomes in a Single Center
Anna Sutton¹, Erin Balay-Dustrude¹, Beth A Mueller¹ and Susan Shenoi², ¹University of Washington, Seattle, WA, ²Seattle Children's Hospital and Research Center, Mercer Island, WA, WA
Background/Purpose: In clinical trials, biologic disease-modifying antirheumatic drugs (bDMARDs) for juvenile idiopathic arthritis (JIA) have demonstrated good efficacy. However, less is known about the impact…
Abstract Number: 0569 • ACR Convergence 2024
The Longitudinal Association Between Disease Activity, Function and Health-Related Quality of Life in Axial Spondyloarthritis: Results from the DESIR Cohort
Augusta Ortolan¹, Desiree van der Heijde², Laure Gossec³ and Sofia Ramiro⁴, ¹Policlinico Universitario Agostino Gemelli IRCSS, Rome, Lazio, Italy, ²Department of Rheumatology, Leiden University Medical Center, Meerssen, Netherlands, ³Sorbonne Université, Paris, France, ⁴Leiden University Medical Center, Bunde, Netherlands
Background/Purpose: Health-related quality of life (HRQoL) in axSpA is considered an overarching outcome, with other disease outcomes contributing to it [1]. To validate a previously…
Abstract Number: 0660 • ACR Convergence 2024
Hydroxychloroquine Users at Lower Risk of Kidney Function Decline in Lupus Nephritis
Shivani Garg¹, Brad Rovin², Brad Astor¹, Tripti Singh¹, Lexie Kolton¹, Callie Saric¹, S. Sam Lim³ and Christie Bartels⁴, ¹University of Wisconsin, School of Medicine and Public Health, Madison, Madison, WI, ²The Ohio State University, Columbus, OH, ³Emory University, Atlanta, GA, ⁴University of Wisconsin School of Medicine and Public Health, Madison, WI
Background/Purpose: Hydroxychloroquine (HCQ) is the cornerstone in treatment of systemic lupus erythematosus (SLE), yet its role in preventing kidney function decline in lupus nephritis (LN)…
Abstract Number: 1060 • ACR Convergence 2024
Therapeutic Hydroxychloroquine Blood Levels Predict Lower Mean Frequency of Recurrent Acute Care Utilization in Lupus
Shivani Garg¹, Giancarlo Valiente², Callie Saric¹, Betty Chewning³ and Christie Bartels⁴, ¹University of Wisconsin, School of Medicine and Public Health, Madison, Madison, WI, ²University of Wisconsin, School of Medicine and Public Health, Madison, ³University of Wisconsin, School of Pharmacy, Madison, ⁴University of Wisconsin School of Medicine and Public Health, Madison, WI
Background/Purpose: Nonadherence to hydroxychloroquine (HCQ) is highly prevalent in lupus (or SLE) and two-fold higher in patients of Black race or Hispanic ethnicity. While HCQ…
Abstract Number: 1342 • ACR Convergence 2024
Utility of Anti-Carbamylated Antibodies in Early Rheumatoid Arthritis in South Asian Population
chandhu aS¹, Josna Joseph¹, ABHILASHA ARVIND MANWATKAR² and John Mathew³, ¹CMC Vellore, Vellore, Tamil Nadu, India, ²christian medical college, vellore, Tamil Nadu, India, ³Christian Medical college , Vellore , India, Vellore, India
Background/Purpose: Rheumatoid Arthritis (RA) is an autoantibody mediated disease with deforming peripheral arthritis. Autoantibodies widely used are rheumatoid factor (RF) and anti-citrullinated peptide antibody (ACPA).…
Abstract Number: 1411 • ACR Convergence 2024
Impact of Patient and Physician Alignment on Sjögren’s Disease Severity, a Real-World Survey on Patients’ Clinical Outcomes and Health-Related Quality of Life
Wan Fai Ng¹, Coralie Bouillot², NICOLA MASSEY³, Megan Hughes³, Victoria Barton³, Giorgio Castellano³, Ana Barat⁴, Gayle Kenney⁵ and Jessica Marvel⁶, ¹Department of Rheumatology, Newcastle University, & HRB Clinical Research Facility, University College Cork, Newcastle upon Tyne, United Kingdom, ²Sjögren Europe, Switzerland, Switzerland, ³ADELPHI REAL WORLD, BOLLINGTON, United Kingdom, ⁴Novartis Ireland Ltd, Dublin, Ireland, ⁵Novartis Pharma AG, Basel, Switzerland, ⁶Novartis, East Hanover, NJ
Background/Purpose: Sjögren’s disease (SjD) has a high disease burden in affected patients, with no licensed treatments currently available. The Clinical EULAR Sjögren’s syndrome disease activity…
Abstract Number: 1698 • ACR Convergence 2024
Assessment of the Remission Maintenance After Tocilizumab Withdrawal in Polymyalgia Rheumatica Patients Receiving a 6-month Treatment
Baptiste Chevet¹, Aghiles Souki², nowak emmanuel², Guillermo CARVAJAL ALEGRIA³, Emmanuelle Dernis⁴, Christophe Richez⁵, Marie-Elise Truchetet⁶, DANIEL WENDLING⁷, ERIC TOUSSIROT⁸, aleth Perdriger⁹, Jacques-Eric Gottenberg¹⁰, Renaud FELTEN¹¹, Bruno Fautrel¹², laurent chiche¹³, Anne Walliser-Lohse¹⁴, Pascal Hilliquin¹⁵, Catherine Le Henaff¹⁶, Benjamin Dervieux¹⁷, Guillaume Direz¹⁸, Isabelle Valckenaere¹⁹, Divi Cornec²⁰, Dewi Guellec²¹, Thierry Marhadou²², Alain SARAUX²³ and Valerie Devauchelle²⁴, ¹University Hospital of Brest, Brest, France, ²Centre Hospitalier Regional Universitaire (CHU) de Brest, Brest, France, ³CHRU de Tours, Tours, France, ⁴CH LE MANS, LE MANS, Pays de la Loire, France, ⁵Université de Bordeaux, Bordeaux, France, ⁶Bordeaux University Hospital, Bordeaux, France, ⁷University Hospital, Besançon, France, ⁸university hospital of BESANCON, besancon, France, ⁹Rennes University, Rennes, France, ¹⁰Rheumatology Department, Strasbourg University Hospital,, Strasbourg, France, ¹¹Hopitaux Universitaires de Strasbourg, STRASBOURG, France, ¹²INSERM, UMRS 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique, and Sorbonne University – Assistance Publique-Hôpitaux de Paris, Département de Rhumatologie, Hôpital Pitié-Salpêtrière, Paris, Ile-de-France, France, ¹³hopital europeen, marseille, France, ¹⁴Hopital Nord Franche-Comté, BELFORT, France, ¹⁵Centre Hospitalier Sud Francilien, Corbeil-Essonnes, France, ¹⁶Hopital de Morlaix, Morlaix, France, ¹⁷CH de Mulhouse - Competence center for autoimmune diseases, Internal Medicine, Mulhouse, France, ¹⁸Hôpital du Mans, Le Mans, France, ¹⁹CHU de Nancy, Nancy, France, ²⁰Service de Rhumatologie, CHU de Brest, Brest, France, ²¹CHU de Brest, Brest, France, ²²CHU Cavale Blanche, Brest, France, ²³CHU Brest, Brest, France, ²⁴UBO, Brest, France
Background/Purpose: The SEMAPHORE trial1 was a randomized controlled prospective study to assess the safety and efficacy (success defined by PMR-AS≤10 and GC≤5mg or GC decrease…

« Previous Page
1
…
7
8
9
10
11
…
102
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].